Bacterial biofilm extracellular matrix protein

**Bacterial biofilm extracellular matrix proteins** are a diverse group of secreted or surface-associated proteins that constitute a core structural and functional component of biofilms—the self-produced, multicellular communities in which many bacteria persist during infection. These proteins include surface adhesins, secreted structural proteins, and protein fibers (such as curli in E. coli, BslA in Bacillus subtilis, Bap1/RbmA/RbmC in Vibrio cholerae, CdrA in Pseudomonas aeruginosa, and BapA in Staphylococcus aureus). They perform crucial roles in: - anchoring cells to surfaces, - stabilizing and cross-linking the matrix with polysaccharides and DNA, - forming 3D architectures, - mediating microbe-host interactions, and - protecting resident bacteria from environmental factors, immune attack, and antibiotics[1][2][5][6]. **These proteins are not a single, conserved molecular target** but a broad functional category. While they are considered attractive targets for anti-biofilm therapeutics due to their essential function in biofilm integrity and infection persistence, the diversity and variability across species, along with the lack of conserved epitopes, present challenges for direct therapeutic targeting[1][2][5]. **Key examples and their functions:** - BslA (Bacillus subtilis): forms a hydrophobic 'raincoat' cover; organizes biofilm architecture[3]. - Curli (E. coli): form amyloid fibers mediating cell adhesion[1]. - Bap1, RbmA, RbmC (V. cholerae): scaffold biofilm matrix and mediate surface/bacterial/host interactions[5]. - CdrA (P. aeruginosa): promotes aggregation and matrix stability[6]. - BapA (S. enterica, S. aureus): mediates surface adhesion and biofilm maturation[4]. The term "Bacterial biofilm matrix and extracellular matrix proteins" is therefore **overly broad**, does not refer to a single molecule or well-defined therapeutic target, and actually encompasses a wide variety of species- and strain-specific proteins with diverse structures and sequences. For target-based drug discovery or biomarker use, it is necessary to specify the matrix protein(s) of interest in the context of a bacterial species or type of infection.

Other names

Biofilm matrix proteinBiofilm ECM proteinBacterial extracellular matrix proteinCurli (for E. coli)Bap1, RbmA, RbmC (for V. cholerae)BslA (for Bacillus subtilis)CdrA (for Pseudomonas aeruginosa)BapA (for Staphylococcus aureus, S. enterica)

Enzyme-mediated degradation of matrix components (e.g., dispersin B cleaves exopolysaccharides, DNase I digests extracellular DNA) Disruption/inhibition of protein-protein or protein-polysaccharide interactions necessary for matrix formation or stability[2][5] Preventing protein assembly (via antibodies, peptides, or inhibitors in research)